Patents Assigned to Keryx
-
Publication number: 20240100011Abstract: Described herein are ferric citrate-containing pharmaceutical compositions (e.g., solid oral dosage forms such as tablets). The pharmaceutical compositions described here can be administered to a subject in need thereof. In particular, the pharmaceutical compositions described here can be administered to a subject who is ? about 18 years of age (e.g., about 6-18 years of age or about 12 to 17 years of age).Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Dragutin KNEZIC, Aniruddh PATEL, Farzaneh SEYEDI, Anandhavalavan ARULMOZHI, Milind DIXIT
-
Publication number: 20190307791Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: December 11, 2018Publication date: October 10, 2019Applicant: KERYX BIOPHARMACEUTICALS, INC.Inventors: Enrique PORADOSU, Ron BENTSUR, James F. OLIVIERO
-
Publication number: 20190269645Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: October 8, 2018Publication date: September 5, 2019Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
-
Patent number: 10300039Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).Type: GrantFiled: May 19, 2016Date of Patent: May 28, 2019Assignee: KERYX BIOPHARMACEUTICALS, INC.Inventor: Henry Trong Le
-
Publication number: 20180071243Abstract: Described herein are methods for treating patients with iron-deficiency anemia (IDA), comprising administering ferric citrate to such patients. In certain aspects, the patients treated for iron-deficiency anemia have a gastrointestinal disorder, such as inflammatory bowel disease, inflammatory bowel syndrome, Crohn's disease, microscopic colitis (such as collagenous or lymphocytic colitis), or chemically-induced colitis (e.g., NSAID (nonsteroidal anti-inflammatory drug)-induced colitis). In certain aspects, the patients treated for iron-deficiency anemia have blood loss associated with childbirth, menstruation or infection. In some aspects, the patients treated for iron-deficiency anemia have insufficient dietary intake of iron and/or insufficient absorption of iron.Type: ApplicationFiled: March 3, 2016Publication date: March 15, 2018Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, Ron Bentsur, Shay David Shemesh
-
Publication number: 20160263075Abstract: The disclosre relates to ferric citrate tablets and dosage forms.Type: ApplicationFiled: May 19, 2016Publication date: September 15, 2016Applicant: KERYX BIOPHARMACEUTICALS, INC.Inventor: Henry Trong Le
-
Publication number: 20160256486Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: November 3, 2014Publication date: September 8, 2016Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, Ron Bentsur, James F. Oliviero, III
-
Patent number: 9387191Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).Type: GrantFiled: July 21, 2010Date of Patent: July 12, 2016Assignee: Keryx Biopharmaceuticals, Inc.Inventor: Henry Trong Le
-
Publication number: 20150079168Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: October 24, 2014Publication date: March 19, 2015Applicant: KERYX BIOPHARMACEUTICALS, INC.Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
-
Publication number: 20140234416Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
-
Publication number: 20120115945Abstract: The disclosure relates to ferric citrate tablets and dosage forms.Type: ApplicationFiled: July 21, 2010Publication date: May 10, 2012Applicant: Keryx Biopharmaceuticals Inc.Inventor: Henry Trong Le
-
Publication number: 20110243933Abstract: Treatment regimens comprising co-treatment of cancer with perifosine and capecitabine are disclosed herein, as well as pharmaceutical compositions and unit dosage forms thereof formulated to be suitable for use in said treatment regimens.Type: ApplicationFiled: March 31, 2011Publication date: October 6, 2011Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Enrique Poradosu, Peeter Sportelli
-
Publication number: 20070173479Abstract: The present invention concerns methods for the treatment of bladder related diseases and, in particular, inflammatory bladder diseases such as interstitial cystitis, by administration of sulodexide.Type: ApplicationFiled: December 9, 2004Publication date: July 26, 2007Applicant: KERYX BIOPHARMACEUTICALS, INC.Inventor: Enrique Poradosu
-
Publication number: 20030078400Abstract: The invention concerns a hardware-software system comprising information on the three-dimensional structure and nature of certain regions in protein kinases. The invention also concerns methods for screening for or synthesizing candidate chemical compounds for regulating kinase activity based on this information.Type: ApplicationFiled: July 26, 2002Publication date: April 24, 2003Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Morris Laster, Dror Tobi
-
Publication number: 20030013680Abstract: The present invention relates to a method for the treatment of HIV-associated nephropathy by administration of glycosaminoglycans, and in particular, by the administration of sulodexide.Type: ApplicationFiled: June 12, 2002Publication date: January 16, 2003Applicant: KeryxInventors: Morris Laster, Noa Shelach
-
Publication number: 20030008844Abstract: The present invention is directed to methods for preventing or treating inflammatory bowel disease by administering a composition comprising a therapeutically or prophylactically effective amount of a composition comprising between about 60% to 90% iduronylglycosaminoglycan sulfate and between about 10% to 40% dermatan sulfate, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof. In a particular embodiment, a therapeutically or prophylactically effective amount of a composition comprising sulodexide, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof is administered. The composition to be administered may also comprise one or more additional active ingredients selected from the group consisting of steroids, aminosalicylates, short-chain fatty acids, thioguanine derivatives, antibiotics, biological agents, antidepressants, and pain-relievers.Type: ApplicationFiled: May 16, 2002Publication date: January 9, 2003Applicant: Keryx Biopharmaceuticals, Inc.Inventors: Michael Spero, Noa Shelach, Morris Laster